

**S1 Table.** Patient characteristics

Characteristic	Total (n=426)	No PORT (n=176)	PORT (n=250)	p-value
Age (yr)				0.942
< 47	203 (47.7)	83 (47.2)	120 (48.0)	
≥ 47	223 (52.3)	93 (52.8)	130 (52.0)	
Clinical T category				> 0.99
T1/2	219 (51.4)	91 (51.7)	128 (51.2)	
T3/4	202 (47.4)	83 (47.2)	119 (47.6)	
Tx	5 (1.2)	2 (1.1)	3 (1.2)	
Clinical N category				< 0.001
N0/1	245 (57.5)	93 (52.8)	83 (33.2)	
N2/3	176 (41.3)	80 (45.5)	165 (66.0)	
Nx	5 (1.2)	3 (1.7)	2 (0.8)	
Metastatic site				0.003
Bone only	158 (37.1)	69 (39.2)	89 (35.6)	
Bone and other	77 (18.1)	43 (24.4)	34 (13.6)	
Other (no bone)	191 (44.8)	64 (36.4)	127 (50.8)	
Metastatic burden <sup>a)</sup>				< 0.001
Single	144 (33.8)	48 (27.3)	96 (38.4)	
Oligo	162 (38.0)	54 (30.7)	108 (43.2)	
Disseminated	119 (27.9)	74 (42.0)	45 (18.0)	
Unknown	1 (0.2)	0	1 (0.4)	
No. of metastases				< 0.001
≤ 5	287 (67.4)	91 (51.7)	196 (78.4)	
> 5	138 (32.4)	85 (48.3)	53 (21.2)	
Unknown	1 (0.2)	0 (0.0)	1 (0.4)	
IHC subtypes				0.733
Luminal A	213 (50.0)	85 (48.3)	128 (51.2)	
Luminal B	87 (20.4)	39 (22.2)	48 (19.2)	
HER2-enriched	67 (15.7)	27 (15.3)	40 (16.0)	
Triple-negative	51 (12.0)	24 (13.6)	27 (10.8)	
Unknown (luminal A or B)	8 (1.9)	1 (0.6)	7 (2.8)	
Chemotherapy				< 0.001
Preoperative	184 (43.2)	44 (25.0)	140 (56.0)	
Postoperative	87 (20.4)	49 (27.8)	38 (15.2)	
Both	129 (30.3)	65 (36.9)	64 (25.6)	
None	26 (6.1)	18 (10.2)	8 (3.2)	
Type of PTR				< 0.001
Breast-conserving	130 (30.5)	30 (17.0)	100 (40.0)	
Mastectomy	296 (69.5)	146 (83.0)	150 (60.0)	
Hormone therapy				0.021
Postoperative	254 (59.6)	94 (53.4)	160 (64.0)	
Preoperative	5 (1.2)	0	5 (2.0)	
Both	25 (5.9)	13 (7.4)	12 (4.8)	
None	142 (33.3)	69 (39.2)	73 (29.2)	
Anti-HER2 therapy				0.628
Postoperative	47 (11.0)	20 (11.4)	27 (10.8)	
Preoperative	8 (1.9)	5 (2.8)	3 (1.2)	
Both	69 (16.2)	26 (14.8)	43 (17.2)	

None	301 (70.7)	125 (71.0)	176 (70.4)	
Unknown	1 (0.2)	0	1 (0.4)	
Intervention to all metastases <sup>b)</sup>				< 0.001
Yes	120 (28.2)	23 (13.1)	97 (38.8)	
No	306 (71.8)	153 (86.9)	153 (61.2)	

Values are presented as number (%). HER2, human epidermal growth factor 2; IHC, immunohistochemistry; PORT, postoperative radiotherapy; PTR, primary tumor resection. <sup>a)</sup>Oligometastases defined according to Kobayashi et al. [1], <sup>b)</sup>Intervention included surgery and/or radiotherapy to metastatic sites. All interventions were performed within 3 months after surgery or postoperative chemotherapy.

#### Reference

1. Kobayashi T, Ichiba T, Sakuyama T, Arakawa Y, Nagasaki E, Aiba K, et al. Possible clinical cure of metastatic breast cancer: lessons from our 30-year experience with oligometastatic breast cancer patients and literature review. *Breast Cancer*. 2012;19:218-37.